The FDA has approved a new option for HIV-1 pre-exposure prophylaxis to reduce HIV-1 infection risk from sex, excluding in those who have receptive vaginal sex.
In his session as IAS 2019, Myron Cohen, MD, discussed new long-acting injectables for HIV prevention and the ongoing trials that will determine the efficacy of each.
The impact of tenofovir-containing pre-exposure prophylaxis on bone mineral density may vary depending on an individual’s adherence. Authors of a new study assessed the effect of the only FDA-approved PrEP...
Researchers from Australia investigated the incidence of and behavioral risk factors associated with STIs, as well as the changes in STI incidence after preexposure prophylaxis initiation.
For the first time, the US Preventive Services Task Force has made recommendations for all at-risk populations of HIV infection to receive PrEP therapy. To see which populations are included in this...
HIV-negative men who receive pre-exposure prophylaxis with tenofovir and emtricitabine do not develop resistance to these drugs, according to new findings.
In an attempt to decrease transmission of HIV and end the current epidemic, major stakeholders are taking steps to increase availability of pre-exposure prophylaxis, although some plans still deny...
